Welgus Howard G. 4

What Happened

• Howard G. Welgus, a director of Arcutis Biotherapeutics (ARQT), was granted two awards on June 5, 2026: 5,778 shares (RSUs) and 16,667 derivative awards, for a combined 22,445 shares. Both were reported as acquired at $0.00 (no cash paid).
• These awards are grants (code A on the Form 4), not open-market purchases or sales. They represent compensation for board service rather than a cash transaction.

Key Details

• Transaction date: June 5, 2026; Form 4 filed June 9, 2026 (reporting date).
• Award amounts and price: 5,778 RSUs @ $0.00; 16,667 derivative awards @ $0.00; total 22,445 shares.
• Vesting/conditions: Per footnotes, the RSUs and the derivative awards vest 100% on the earlier of the first anniversary of the grant date (June 5, 2026 as noted) or immediately before the next annual meeting of stockholders, subject to continued service through the vesting date.
• Shares owned after the transaction: not disclosed in the provided excerpt.
• No sale, purchase, or exercise-for-cash reported; this is a compensation grant.

Context

• RSU and derivative grants are common director compensation and do not require immediate cash outlay; they convert to shares upon vesting if service conditions are met.
• Because this filing reports awards (not sales), it reflects compensation rather than an expressed view to buy or sell stock.